News & Updates

Monotherapy with rivaroxaban in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) appears to protect against the risks of major adverse cardiovascular event (MACE) and major bleeding, with the benefit observed across the broad range of age, according to a post hoc analysis of the open-label AFIRE* trial.

Vape or e-cigarette is a rather recent arrival in the nicotine delivery route. As such, little is known about the long-term effects of vaping. However, developments in recent years have brought vaping to the limelight as it is becoming increasingly obvious that the vape industry is targeting youth. Initially unintentional, but increasingly deliberate as it became obvious that youth were a valuable source of current and future income. 

The combination of sintilimab plus axitinib demonstrates encouraging antitumour activity in patients with fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) while having a manageable safety profile, according to a phase II study conducted in China.

The use of glucagon-like peptide 1 (GLP-1) drugs such as semaglutide, dulaglutide, and the dual agonist tirzepatide helps boost testosterone levels in men with obesity and type 2 diabetes (T2D), according to new research.

Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) can set up an immunosuppressive microenvironment in the lung via arginase-1 (ARG-1) bronchiectasis, which is linked to clinical outcomes and response to antibiotic treatment among patients with bronchiectasis, suggests a study.

Treatment with tofacitinib demonstrates effectiveness in patients with Blau syndrome (BS) who are resistant to tumor necrosis factor inhibitors (TNFi) or corticosteroids, reports a recent study.

An 8-week exercise-based prehabilitation program helps enhance exercise capacity, muscle function, and muscle size in kidney transplant candidates, including those with frailty, according to the FRAILMar study.